Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.5%

1 terminated/withdrawn out of 22 trials

Success Rate

94.4%

+7.9% vs industry average

Late-Stage Pipeline

68%

15 trials in Phase 3/4

Results Transparency

0%

0 of 17 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
15(78.9%)
Phase 2
3(15.8%)
N/A
1(5.3%)
19Total
Phase 4(15)
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT00404989Recruiting

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.

Role: collaborator

NCT06871592Not Yet Recruiting

Quantified Evaluation of Whole Face 8-points Supra-periosteum High Molecular Weight Hyaluronic Acid Injection in Asian

Role: collaborator

NCT06600282Phase 4Not Yet Recruiting

Bioequivalence of Two Formulations of Parecoxib in Healthy Volunteers Under Fasting Conditions

Role: lead

NCT06161792Phase 2Terminated

Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer

Role: lead

NCT05654090Phase 4Unknown

Evaluate Bioequivalence of Burotam (1/1 g/Vial)

Role: lead

NCT05496725Phase 4Completed

Evaluate Bioequivalence of Micafungin (50mg/Vial)

Role: lead

NCT03342456Phase 4Completed

The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers

Role: collaborator

NCT02100540Phase 2Completed

A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women

Role: lead

NCT05040594Not ApplicableCompleted

Evaluate the Efficacy and Safety of Lidocaine-Containing Hyaluronic Acid Filler in the Treatment of Nasolabial Folds.

Role: lead

NCT04585412Phase 4Completed

Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)

Role: lead

NCT04671563Phase 4Completed

Pharmacokinetics of Two Formulation of Tenofovir Disoproxil Fumarate

Role: lead

NCT04552353Phase 4Completed

Evaluate Bioequivalence of Voriconazole(200mg/Vial) .

Role: lead

NCT03826316Phase 4Completed

Pharmacokinetics of Nalbuphine Injection

Role: lead

NCT03712475Phase 4Completed

Pharmacokinetics of Two Formulation of Pregabalin

Role: lead

NCT02972216Completed

Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy

Role: lead

NCT02912156Phase 4Completed

Pharmacokinetics of Two Different Formulation of Voriconazole

Role: lead

NCT02850848Phase 4Completed

Pharmacokinetics of Two Formulations of Entecavir

Role: lead

NCT02207881Phase 2Completed

A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis

Role: lead

NCT02543606Phase 4Completed

Bioequivalence of Two Formulations of Esomeprazole

Role: lead

NCT02344563Phase 4Completed

Bioequivalence of Two Formulations of Meropenem Intravenous Injection

Role: lead